Novartis AG agreed to acquire AveXis Inc for US$8.7 billion to gain a promising drug to treat a rare disease that afflicts infants, hastening a shift toward gene therapy and precision medicines.
Shareholders of the Bannockburn, Illinois-based company would receive US$218 a share in cash in a tender offer, Novartis said in a statement yesterday.
The price is 88 percent above where AveXis closed on Friday.
The transaction is Novartis’ second deal to advance in gene therapy this year — and the first led by new chief executive officer Vas Narasimhan.
The Swiss drugmaker is redeploying some of the US$13 billion in proceeds from the sale of its stake in a consumer-health joint venture to partner GlaxoSmithKline PLC to gain more firepower in prescription medicines before some of its existing best-sellers lose patent protection.
“Our goal is to build on a core of medicines as a medicines company powered by data and digital,” Narasimhan said in a conference call with investors. “A deal like this fits right in that sweet spot.”
AveXis is developing a product to treat spinal muscular atrophy, an inherited neurodegenerative disease caused by a defect in a single gene, which shows the potential to become a blockbuster, a Novartis statement said.
In buying AveXis, the Swiss drugmaker is also gaining the company’s AVXS-101 product to address a rare disease. Like gene therapies, such treatments command high prices that have sparked interest even from unexpected players in the industry.
AveXis also has valuable manufacturing and research capabilities that would give its Swiss buyer a platform alongside its research on chimeric antigen receptor T-cell therapy (CAR-T) in cancer “to advance a growing pipeline of gene therapies across therapeutic areas,” Narasimhan said.
Novartis’ Kymriah won US regulatory approval in August last year, making it the first drug approved from a new class of treatments called CAR-Ts that have been heralded as a promising approach to treating and potentially curing cancers as well as genetic conditions such as blindness. Like other gene therapies, it is used only once on a patient, and thus carries a high price tag — US$475,000, in the case of Kymriah.
AVXS-101 helped a small group of babies with spinal muscular atrophy hit development milestones at a rate previously unseen, a study showed in November last year.
The first medication for the disease, Biogen Inc’s Spinraza, won approval less than a year ago. Babies with the most severe form of the disease typically die before age two.
“This acquisition makes strategic sense,” Vontobel AG analyst Stefan Schneider wrote in a note to clients.
Novartis’ drugs Gilenya and Afinitor would probably face competition from cheaper generics next year — about the same time that AveXis’ first experimental drug might reach the market, Schneider said.
The domestic unit of the Chinese-owned, Dutch-headquartered chipmaker Nexperia BV will soon be able to produce semiconductors locally within China, according to two company sources. Nexperia is at the center of a global tug-of-war over critical semiconductor technology, with a Dutch court in February ordering a probe into alleged mismanagement at the company. The geopolitical tussle has disrupted supply chains, with some carmakers reportedly forced to cut production due to chip shortages. Local production would allow Nexperia’s domestic arm, Nexperia Semiconductors (China) Ltd (安世半導體中國), to bypass restrictions in place since October on the supply of silicon wafers — etched with tiny components to
Singapore-based ride-hailing and delivery giant Grab Holdings Ltd has applied for regulatory approval to acquire the Taiwan operations of Germany-based Delivery Hero SE's Foodpanda in a deal valued at about US$600 million. Grab submitted the filing to the Fair Trade Commission on Friday last week, with the transaction subject to regulatory review and approval, the company said in a statement yesterday. Its independent governance structure would help foster a healthy and competitive market in Taiwan if the deal is approved, Grab said. Grab, which is listed on the NASDAQ, said in the filing that US-based Uber Technologies Inc holds about 13 percent of
Taiwan is open to joining a global liquefied natural gas (LNG) program if one is created, but on the condition that countries provide delivery even in a scenario where there is a conflict with China, an energy department official said yesterday. While Taiwan’s priority is to have enough LNG at home, the nation is open to exploring potential strategic reserves in other countries such as Japan or South Korea, Energy Administration Deputy Director-General Chen Chung-hsien (陳崇憲) said. While the LNG market does not have a global reserve for emergencies like that of oil, the concept has been raised a few times —
Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) yesterday received government approval to deploy its advanced 3-nanometer (3nm) process at its second fab currently under construction in Japan, the Ministry of Economic Affairs said in a news release. The ministry green-lit the plan for the facility in Kumamoto, which is scheduled to start installing equipment and come online in 2028 with a monthly production capacity of 15,000 12-inch wafers, the ministry said. The Department of Investment Review in June 2024 authorized a US$5.26 billion investment for the facility, slated to manufacture 6- to 12nm chips, significantly less advanced than 3nm process. At a meeting with
RSS